September 7, 2018
Genetic Signatures article from The Australian Financial Review.
Genetic Signatures featured in The Australian Financial Review.
For more information click the link: Winning the war on superbugs
September 5, 2018
Genetic Signatures’ CEO Dr. John Melki presenting at the inaugural ASX Small and Mid-Cap Conference 6th September, Sydney, Australia.
Join ASX for the inaugural ASX Small and Mid-Cap Conference, showcasing emerging leaders in the small and mid-cap category. This is a unique opportunity to hear from a broad range of ASX-listed companies and their CEOs in the comfortable surrounds of the International Convention Centre at Darling Harbour.
This conference aims to welcome over 400 attendees from the finance industry, with an emphasis on SMSF / sophisticated investors.
Visit John and the team to learn more about the directions of Genetic Signatures.
For more information regarding the conference click here, and the presentation may be viewed here
August 28, 2018
Genetic Signatures (ASX:GSS) – Appendix 4E and 2018 Financial Report
August 28, 2018
Genetic Signatures (ASX:GSS) – Appendix 4G and 2018 Corporate Governance Statement
August 24, 2018
Genetic Signatures (ASX:GSS) – Additional Tax Incentive from understatement FY17 R&D Claim
August 15, 2018
Genetics Signatures (GSS) Investor Presentation
August 2, 2018
Genetics Signatures (GSS) Announces – Major Customer Contract Signed, New Kit and Instrument
July 27, 2018
Genetics Signatures GSS – Appendix 4C Quarterly Report June 2018
May 23, 2018
Genetic Signatures (ASX: GSS) Investor Presentation, May 2018
May 15, 2018
Genetic Signatures (ASX: GSS) TGA Registration for Superbug Detection Kit
Genetic Signatures Limited (ASX: GSS) TGA Registration for Superbug Detection Kit
